Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is scheduled to report its Q2 earnings results on August 21, 2026 after market close.
At publication ·
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) · earnings preview
At a glance
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is scheduled to report its Q2 earnings results on August 21, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.09, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
The stock currently trades at $2.35 with a market capitalization of $108.5M.
Ahead of Inhibikase Therapeutics, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Inhibikase Therapeutics, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q2 (Aug 2026) | $-0.11 | $-0.09 | -22.2% |
| Q1 (May 2026) | $-0.10 | $-0.10 | +0.0% |
| Q1 (Mar 2026) | $-0.10 | $-0.12 | +16.7% |
Related Tools: Earnings Calendar | View IKT Stock Page
Check the latest earnings dates on our IKT earnings page or the Earnings Calendar.
See the full Q2 results including EPS actual vs estimate on our IKT earnings page.
Current market data
NASDAQ · IKT
Keep reading
earnings ·
earnings ·
price ·
sec_filing ·
